Short Duration Therapy of Acute Hepatitis C Genotypes 1 or 4
Status:
Completed
Trial end date:
2019-09-16
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the rate of sustained virological response (SVR) 12
weeks after 8-week oral treatment with grazoprevir 100mg/elbasvir 50mg (MRK-combo) in
patients with acute hepatitis C genotype1 or 4.
Phase:
Phase 2
Details
Lead Sponsor:
Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba
Collaborators:
Institut National de la Santé Et de la Recherche Médicale, France Merck Sharp & Dohme Corp.